[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635639":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":44,"collaborators":10,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Waid City Hospital, Zurich","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with IgA Nephropathie and a therapy with Sparsentan",null,[12],"Drug: sparsentan",[14,19],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","sparsentan","Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR",[9],{"type":15,"name":16,"description":20,"armGroupLabels":21,"otherNames":10},"follow up observation of Albuminuria and GFR in IgA patients in therapy with sparsentan",[9],[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Andi Schleich","CONTACT","+41 44 416 21 55","Andreas.schleich@stadtspital.ch",[29],{"facility":30,"status":10,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Stadtspital Zurich","Zurich","Canton of Zurich","8000","Switzerland",{"type":36,"coordinates":37},"Point",[38,39],8.55,47.36667,{"lat":39,"lon":38},[42],{"name":24,"role":25,"phone":43,"phoneExt":10,"email":27},"+41 44 417 21 55",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Schleich Andreas","MD","100635639",false,"NCT07555301","Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy","SWIAN","Inclusion Criteria:\n\n* IgA Nephropathy, Use of Sparsentan\n\nExclusion Criteria:\n\n* age \\\u003C 18y","ALL","18 Years",{"count":57,"type":58},50,"ESTIMATED","OBSERVATIONAL","An observational study tracking the clinical course of patients with IgA nephropathy.",[62],"IgA Nephropathy (IgAN)","NOT_YET_RECRUITING","2026-04-21",{"date":66,"type":67},"2026-04-29","ACTUAL",{"date":69,"type":58},"2026-06-01",{"date":71,"type":58},"2029-12-31",{"name":5,"class":6},1]